Health Economics›Multiple myeloma›First-line therapy quadruplets

First-line therapy quadruplets

Multiple myeloma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-KRd Variant #01	—	R 507 510	28d	—	—	—	—	—
Dara-VMP Variant #01	—	R 432 208	42d	—	83.0 mo	—	—	3
Dara-VTD Variant #01	—	R 328 128	28d	—	—	—	—	1
KRdc Variant #01	—	R 185 821	28d	—	—	—	—	2
Dara-RVd Variant #01	—	R 165 398	21d	—	—	—	—	—
CYKLONE Variant #01	—	R 159 718	28d	—	—	—	—	—
VMPT Variant #03	—	R 19 167	42d	—	—	—	—	2
Dara-VMP (SC daratumumab) Variant #01 Partial	—	R 12 911	42d	—	—	—	—	—
Isa-RVd Variant #03 Partial	—	R 10 956	28d	—	—	—	—	2
Dara-RVd (SC daratumumab) Variant #01 Partial	—	R 10 409	28d	—	—	—	—	1
RVDC Variant #01	—	R 8 398	21d	—	—	—	—	—

11 of 11 regimens shown